RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery
2019-01-01 Catuogno, S.; Di Martino, M. T.; Nuzzo, S.; Esposito, C. L.; Tassone, P.; de Franciscis, V.
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity
2006-01-01 Casadonte, F; Gaspari, M; Arcone, R; Malara, N; Paolino, D; Fresta, M; Tassone, P; Venuta, S; Savino, R; Terracciano, R
Analysis of miRNA, mRNA, and TF interactions through network-based methods
2015-01-01 Cannataro, M; Di Martino, Mt; Tassone, P; Tagliaferri, P; Guzzi, P
ANALYSIS OF PERIPHERAL-BLOOD NORMAL AND MALIGNANT-CELLS WITH THE NOVEL MURINE MONOCLONAL-ANTIBODY UN2
1994-01-01 Tassone, P; Bonelli, P; Tuccillo, F; Turco, Mc; Derosa, G; Morrone, G; Cecco, L; Cerra, M; Petrella, A; Nigro, M; Venuta, S
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
2017-01-01 Pastina, P; Nardone, V; Croci, S; Battaglia, G; Vanni, F; Bellan, C; Barbarino, M; Ricci, V; Costantini, S; Capone, F; Botta, C; Zarone, Mr; Misso, G; Boccellino, M; Caraglia, M; Giordano, A; Paladini, P; Tassone, P; Cusi, Mg; Pirtoli, L; Correale, P; Tagliaferri, P
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
2009-01-01 Fulciniti, M; Tassone, P; Hideshima, T; Vallet, S; Nanjappa, P; Ettenberg, Sa; Shen, Z; Patel, N; Tai, Yt; Chauhan, D; Mitsiades, C; Prabhala, R; Raje, N; Anderson, Kc; Stover, Dr; Munshi, Nc
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma
2019-01-01 Juli, G; Oliverio, M; Bellizzi, D; Gallo Cantafio, Me; Grillone, K; Passarino, G; Colica, C; Nardi, M; Rossi, M; Procopio, A; Tagliaferri, P; Tassone, P; Amodio, N
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways
2005-01-01 Tagliaferri, P; Blotta, S; Viscomi, C; Grillone, F; Budillon, A; Caraglia, M; Venuta, S; Tassone, P
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia
2015-01-01 Maura, F; Cutrona, G; Mosca, L; Matis, S; Lionetti, M; Fabris, S; Agnelli, L; Colombo, M; Massucco, C; Ferracin, M; Zagatti, B; Reverberi, D; Gentile, M; Recchia, Ag; Bossio, S; Rossi, D; Gaidano, G; Molica, S; Cortelezzi, A; Di Raimondo, F; Negrini, M; Tassone, P; Morabito, F; Ferrarini, M; Neri, A
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
2016-01-01 Mignogna, C; Staropoli, N; Botta, C; De Marco, C; Rizzuto, A; Morelli, M; Di Cello, A; Franco, R; Camastra, C; Presta, I; Malara, N; Salvino, A; Tagliaferri, Piersandro; Tassone, P; Di Vito, A; Donato, G; Barni, T
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery | 1-gen-2019 | Catuogno, S.; Di Martino, M. T.; Nuzzo, S.; Esposito, C. L.; Tassone, P.; de Franciscis, V. | |
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity | 1-gen-2006 | Casadonte, F; Gaspari, M; Arcone, R; Malara, N; Paolino, D; Fresta, M; Tassone, P; Venuta, S; Savino, R; Terracciano, R | |
Analysis of miRNA, mRNA, and TF interactions through network-based methods | 1-gen-2015 | Cannataro, M; Di Martino, Mt; Tassone, P; Tagliaferri, P; Guzzi, P | |
ANALYSIS OF PERIPHERAL-BLOOD NORMAL AND MALIGNANT-CELLS WITH THE NOVEL MURINE MONOCLONAL-ANTIBODY UN2 | 1-gen-1994 | Tassone, P; Bonelli, P; Tuccillo, F; Turco, Mc; Derosa, G; Morrone, G; Cecco, L; Cerra, M; Petrella, A; Nigro, M; Venuta, S | |
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. | 1-gen-2017 | Pastina, P; Nardone, V; Croci, S; Battaglia, G; Vanni, F; Bellan, C; Barbarino, M; Ricci, V; Costantini, S; Capone, F; Botta, C; Zarone, Mr; Misso, G; Boccellino, M; Caraglia, M; Giordano, A; Paladini, P; Tassone, P; Cusi, Mg; Pirtoli, L; Correale, P; Tagliaferri, P | |
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma | 1-gen-2009 | Fulciniti, M; Tassone, P; Hideshima, T; Vallet, S; Nanjappa, P; Ettenberg, Sa; Shen, Z; Patel, N; Tai, Yt; Chauhan, D; Mitsiades, C; Prabhala, R; Raje, N; Anderson, Kc; Stover, Dr; Munshi, Nc | |
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma | 1-gen-2019 | Juli, G; Oliverio, M; Bellizzi, D; Gallo Cantafio, Me; Grillone, K; Passarino, G; Colica, C; Nardi, M; Rossi, M; Procopio, A; Tagliaferri, P; Tassone, P; Amodio, N | |
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways | 1-gen-2005 | Tagliaferri, P; Blotta, S; Viscomi, C; Grillone, F; Budillon, A; Caraglia, M; Venuta, S; Tassone, P | |
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia | 1-gen-2015 | Maura, F; Cutrona, G; Mosca, L; Matis, S; Lionetti, M; Fabris, S; Agnelli, L; Colombo, M; Massucco, C; Ferracin, M; Zagatti, B; Reverberi, D; Gentile, M; Recchia, Ag; Bossio, S; Rossi, D; Gaidano, G; Molica, S; Cortelezzi, A; Di Raimondo, F; Negrini, M; Tassone, P; Morabito, F; Ferrarini, M; Neri, A | |
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients | 1-gen-2016 | Mignogna, C; Staropoli, N; Botta, C; De Marco, C; Rizzuto, A; Morelli, M; Di Cello, A; Franco, R; Camastra, C; Presta, I; Malara, N; Salvino, A; Tagliaferri, Piersandro; Tassone, P; Di Vito, A; Donato, G; Barni, T |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 316
- 1 Contributo su Rivista::1.1 Arti... 316
Data di pubblicazione
- 2020 - 2024 51
- 2010 - 2019 159
- 2000 - 2009 86
- 1990 - 1999 18
- 1982 - 1989 2
Editore
- PERGAMON-ELSEVIER SCIENCE LTD, TH... 1
Rivista
- BLOOD 23
- ONCOTARGET 18
- LEUKEMIA 17
- CLINICAL CANCER RESEARCH 16
- CANCERS 11
- CANCER BIOLOGY & THERAPY 10
- CURRENT CANCER DRUG TARGETS 7
- MOLECULAR THERAPY NUCLEIC ACIDS 6
- BRITISH JOURNAL OF CANCER 5
- BRITISH JOURNAL OF HAEMATOLOGY 5
Keyword
- multiple myeloma 13
- Humans 9
- Multiple myeloma 8
- microRNA 7
- Multiple Myeloma 7
- immunotherapy 6
- cancer 5
- miRNA 5
- Apoptosis 4
- Cancer 4
Lingua
- eng 264
- ita 2
Accesso al fulltext
- no fulltext 316